Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




MicroRNA Panel Identifies Mild Brain Trauma in a Mouse Model

By LabMedica International staff writers
Posted on 23 Nov 2014
A study conducted on a mouse model found that a panel of 13 serum microRNAs (miRNAs) could be used to identify the severity of damage to the brain and the risk of developing adverse effects following mild traumatic brain injury (mTBI).

MTBI is a heterogeneous injury that may lead to the development of neurological and behavioral disorders. More...
In the absence of specific diagnostic markers, mTBI is often unnoticed or misdiagnosed. Previous research had found a link between microRNAs—snippets of about 20 nucleotides that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA—and post-traumatic stress disorder. Therefore, investigators at the Uniformed Services University of the Health Sciences (Bethesda, MD, USA) sought to identify a similar relationship between miRNAs and mTBI.

MTBI was induced in test animals by varying the weight and fall height of an impactor rod. This treatment caused four different severity grades of mTBI. Injuries were characterized as mild by neurobehavioral severity assessment one day after the injury. All of the animals recovered after day one with no significant neurobehavioral alteration by day 30 post injury.

Results from serum miRNA profiles, which were published in the November 7, 2014, online edition of the journal PLOS ONE, clearly differentiated injured from uninjured animals. Overall, the number of miRNAs that were significantly modulated in injured animals compared to controls increased with the severity of the injury. Thirteen miRNAs were found to identify mTBI regardless of its severity within the mild spectrum of injury. Bioinformatics analyses revealed that the more severe brain injuries were associated with a greater number of miRNAs involved in brain related functions.

Senior author Dr. Radha K. Maheshwari, professor of pathology at the Uniformed Services University of the Health Sciences, said, “This important finding is a step forward in identifying objective biomarkers for mTBI that may be further validated to accurately and cost-effectively identify mTBI in service members and civilians with brain injuries. Our current effort is to identify the precise role these microRNAs play in mTBI which may help in development of mTBI therapies.”

Related Links:

Uniformed Services University of the Health Sciences



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.